Islatravir
Phase 3Small molecule
Merck & Co.Islatravir is a small molecule that works as a NRTTI.[2] It is being investigated across 3 indications, with its most advanced program in Phase 3.[1]
Islatravir is one of 112 small molecule programs targeting HIV-1 infection. It is currently in Phase 3.
3
Indications
13
Total Trials
0
Active Trials
111
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
296 competitors in Immunodeficiency
#DrugCompanyPhaseTrials
1Isentress
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Vemlidy
GileadPhase 3
Valtrex
GGlaxo Dba Glaxosmithkline
Phase 3
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Igpro20
CSL BehringPhase 3
CAB LA
GSKPhase 3
GAMUNEX-C
Grifols Therapeutics LLCPhase 3
Immunoglobulin G
CSL BehringPhase 3
PPSV23
Merck & Co.Phase 3
BIC/FTC/TAF
Merck & Co.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Immunodeficiency5 trials
Combination Therapy1 trial
4 more indications
Renal Impairment1 trial
HIV-1 infection1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Islatravir. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- NRTTI[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company